Literature DB >> 12379948

Does the neuropeptide somatostatin have therapeutic potential against schistosomiasis?

Shyama Chatterjee1, Amadou Mbaye, Joris G De Man, Eric A E Van Marck.   

Abstract

The neuropeptide hormone somatostatin is used to treat bleeding oesophageal varices and to reduce portal pressure, and can prevent progression to severe fibrosis in chronic liver disease. We believe that somatostatin can also have therapeutic potential against schistosomiasis, based on recent observations that severe morbidity symptoms are associated with low levels of host somatostatin in patients infected with Schistosoma mansoni. The administration of exogenous doses of this neuropeptide could therefore alleviate the pathology caused by schistosomiasis.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12379948     DOI: 10.1016/s1471-4922(02)02294-8

Source DB:  PubMed          Journal:  Trends Parasitol        ISSN: 1471-4922


  4 in total

1.  Imaging schistosomes in vivo.

Authors:  Greice Krautz-Peterson; David Ndegwa; Kristine Vasquez; Houari Korideck; Jun Zhang; Jeffrey D Peterson; Patrick J Skelly
Journal:  FASEB J       Date:  2009-04-03       Impact factor: 5.191

2.  The therapeutic effect of the neuropeptide hormone somatostatin on Schistosoma mansoni caused liver fibrosis.

Authors:  Shyama Chatterjee; Gunther Vrolix; Inge Depoortere; Theo Peeters; Eric Van Marck
Journal:  BMC Infect Dis       Date:  2005-06-10       Impact factor: 3.090

3.  Can somatostatin control acute bleeding from oesophageal varices in Schistosoma mansoni patients?[ISRCTN63456799].

Authors:  Shyama Chatterjee; Eric Van Marck
Journal:  BMC Infect Dis       Date:  2004-12-13       Impact factor: 3.090

4.  Eugenol, a potential schistosomicidal agent with anti-inflammatory and antifibrotic effects against Schistosoma mansoni, induced liver pathology.

Authors:  Asmaa M El-Kady; Alzahraa Abdelraouf Ahmad; Tasneem M Hassan; Heba E M El-Deek; Samer S Fouad; Sultan S Althagfan
Journal:  Infect Drug Resist       Date:  2019-03-28       Impact factor: 4.003

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.